First-episode psychosis: an inflammatory state?

Area of Science:

• Neuroscience
• Psychiatry
• Immunology

Background:

• Research increasingly links inflammation to psychiatric disorders.
• The role of inflammation in psychosis remains unclear, with mixed findings.
• First-episode psychosis studies help avoid confounding factors like illness duration and chronic medication.

Purpose of the Study:

• To review studies on inflammation in first-episode psychosis.
• To clarify the pathophysiological role of inflammation in psychosis onset.
• To explore associations between inflammatory markers, symptoms, physical health, and medication effects.

Main Methods:

• Systematic review of studies on inflammation in first-episode psychosis.
• Analysis of inflammatory markers such as IL-6, TNF-α, and IL-1β.
• Discussion of findings related to clinical symptoms, physical health, and antipsychotic effects.

Main Results:

• Consistent elevation of Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha (TNF-α), and Interleukin-1 beta (IL-1β) in first-episode psychosis.
• Varied findings for other cytokines, potentially due to methodological differences.
• Inflammation is associated with clinical symptoms and physical health in psychosis.

Conclusions:

• Elevated inflammation at psychosis onset suggests underlying biological abnormalities.
• Inflammation may be a shared pathophysiological factor across psychiatric conditions like depression and psychosis.
• Future research should explore inflammation as a biomarker and therapeutic target for psychosis.